Lisraya (brepocitinib)
Priovant Therapeutics
ApprovedAug 27, 2026
Marketer take
An oral treatment for dermatomyositis, a condition with few approved options (IVIG is one), so rheumatology and dermatology teams will need education on diagnosis and where an oral therapy fits.
- Sponsor company
- Priovant Therapeutics
- Indication
- To treat dermatomyositis in adults
- Therapeutic area
- Immunology, Dermatology
- Event
- FDA approval
- Date
- Aug 27, 2026
- Status
- Approved
- Source
- FDA page
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?